Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of ...
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the ...
Did you know that you can play the best online slots for free? That’s right, using something known as demo technology, you can spin the reels of the industry’s finest without spending a penny.
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiac condition and the leading cause of sudden cardiac death (SCD) in young adults. Given that SCD can be the first and most ...
The Demonstration Kitchen strives to make cooking accessible to everyone, by demonstrating delicious recipes and menus that are quick, easy and affordable. Our Student Cooking Instructors will provide ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
A visual novel from Orcsoft Team Goblin. Games metadata is powered by IGDB.com We may earn a commission when you buy through links on our sites. ©2025 KOTAKU USA LLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback